#oncology #Australia #Sydney #Kazia Therapeutics #Dr. Sudha Rao

Kazia's New Leadership in Oncology Research

Kazia Therapeutics, a promising player in the clinical-stage oncology sector, has made a significant move by appointing Dr. Sudha Rao as its new Chief Scientific Officer (CSO). With her extensive background in biotechnology and clinical development, Dr. Rao is set to lead the company into its next phase of innovation in cancer therapies, targeting areas of oncology where there is a high unmet need.

Dr. Rao is renowned for her role in developing the epigenetic framework that supports paxalisib, a key therapy being advanced by Kazia. Her experience in creating next-generation therapeutic platforms, notably in PD-L1 protein degradation and SETDB1-targeted chromatin modulation, marks her as an invaluable asset to Kazia's leadership team. Her deep expertise in translational epigenetics and pioneering approaches to AI-guided drug discovery align perfectly with Kazia's goals to integrate cutting-edge science with practical medicine solutions.

In her previous roles, Dr. Rao has shown remarkable capability, bringing over two decades of experience in pharmaceuticals and biotechnology. Currently, she directs the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer Medical Research Institute, where her extensive work has laid foundational insights into cancer genomics. Before this, she contributed to one of the groundbreaking clinical genomics platforms during her tenure at Sanofi/Rhône-Poulenc in the UK.

As a founder of EpiAxis Therapeutics, Dr. Rao successfully advanced various first-in-class epigenetic therapies into early clinical trials, including an impactful Phase 1b study of an LSD1 inhibitor in the treatment of metastatic breast cancer. Her impressive portfolio also includes 39 international patents and an array of high-impact publications in prestigious journals such as Science, Nature, and Immunity.

At Kazia, Dr. Rao will lead the company's R&D initiatives, directly influencing the trajectory of their drug pipeline and enhancing platform capabilities. She will oversee the development of key therapeutic programs:

• - Paxalisib: This dual inhibitor targets the PI3K/mTOR pathway and is currently being investigated across several oncology indications, including advanced breast cancer.
• - NDL2: A novel platform aimed at degrading PD-L1 proteins to tackle immunotherapy resistance and tumor progression.
• - MSETC: This groundbreaking program targets the SETDB1 gene, designed to reverse immune evasion mechanisms.

Dr. Rao's scientific endeavors not only fuel Kazia's strategy but are pivotal in improving epigenetic reprogramming, refining the approach to cancer treatment beyond mere pathway inhibition. "We are developing a platform centered on precision medicine that leverages epigenomics and AI-driven drug discovery to hasten the delivery of novel treatments," Dr. Rao elaborated, expressing her enthusiasm about her new role at Kazia.

Furthermore, she will also focus on advancing Kazia's biomarker strategy, fostering external scientific collaborations, and cultivating strategic partnerships that can propel the company’s growth in oncology. Her leadership is expected to provide clarity in clinical translations while optimizing the patient selection process and target engagement in real-time.

As the CEO of Kazia, Dr. John Friend stated, "Dr. Rao embodies the spirit of innovation that is necessary for advancing our oncology initiatives. Her extensive expertise, particularly in linking epigenetics with therapy, will not only strengthen our current projects but also sharpen our future strategic focus."

As Kazia moves forward under the guidance of Dr. Rao, the company is poised to make meaningful contributions to oncology, potentially transforming the landscape for patients facing challenging cancer diagnoses. The integration of epigenetic insights with cutting-edge technology exemplifies Kazia's commitment to precision medicine and their drive to alleviate the burden of cancer.

For further information about Kazia Therapeutics and its expanding portfolio, visit Kazia Therapeutics or follow them on X @KaziaTx.